FORBES-TATE for ELI LILLY AND COMPANY FKA LILLY USA, LLC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| KRISTINA DUNKLIN | — |
| ELIZABETH GREER | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
Medicare/Medicaid MMM
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| KRISTINA DUNKLIN | — |
| ELIZABETH GREER | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
Budget/Appropriations BUD
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (PL 119-21).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| KRISTINA DUNKLIN | — |
| ELIZABETH GREER | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.